Mutual of America Capital Management LLC Sells 7,740 Shares of Illumina, Inc. $ILMN

Mutual of America Capital Management LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 70,983 shares of the life sciences company’s stock after selling 7,740 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Illumina were worth $6,741,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ILMN. AQR Capital Management LLC grew its holdings in Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the period. Edmond DE Rothschild Holding S.A. boosted its position in shares of Illumina by 140.1% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after purchasing an additional 833,750 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock worth $69,528,000 after purchasing an additional 684,802 shares during the period. Pacer Advisors Inc. bought a new stake in Illumina in the third quarter valued at about $61,663,000. Finally, PGGM Investments lifted its stake in Illumina by 115.1% in the second quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company’s stock valued at $109,665,000 after buying an additional 614,973 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 0.6%

ILMN opened at $152.09 on Wednesday. The stock has a market capitalization of $23.24 billion, a P/E ratio of 34.10, a P/E/G ratio of 2.53 and a beta of 1.41. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The firm’s fifty day simple moving average is $136.46 and its 200 day simple moving average is $114.09.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter last year, the business posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Scott Gottlieb purchased 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.17% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. TD Cowen restated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. UBS Group lifted their price objective on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Stifel Nicolaus upped their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Guggenheim increased their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday. Finally, Robert W. Baird set a $109.00 price target on shares of Illumina in a report on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $127.18.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.